Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01327911 · ClinicalTrials.gov registry record · Phase 1
Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel)
A Phase 1 study, sponsored by Neurotech Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT01327911 is a Phase 1 study that has completed, run by Neurotech Pharmaceuticals. The registered enrollment target is 7 participants.
The verdict
NCT01327911, a Phase 1 study, has completed, sponsored by Neurotech Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study is a phase 1, open label, non-randomized, multi-center, pilot study to evaluate the safety and tolerability of NT-501 implants in 5-7 study participants with Mactel.
Interventions
- BIOLOGICAL NT-501 implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2011-05 |
| Est. Completion | 2016-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01327911
The ClinicalTrials.gov registry entry for NCT01327911 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurotech Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NT-501 implant is the first listed.
NCT01327911 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01327911 about?
NCT01327911 is a clinical study titled "Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel)". This study is a phase 1, open label, non-randomized, multi-center, pilot study to evaluate the safety and tolerability of NT-501 implants in 5-7 study participants with Mactel.
What is the current status of trial NCT01327911?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2011-05. Estimated completion is 2016-09.
What interventions are being tested in trial NCT01327911?
The interventions under investigation include: NT-501 implant (BIOLOGICAL).
Who is sponsoring clinical trial NCT01327911?
This trial is sponsored by Neurotech Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.